Bookmark and Share

BioActivity Data for Compound Demeclocycline (CID 54680690)

BioActivity Outcomes:
Active(11)
 
 
Inactive(57)
 
 
Inconclusive(14)
 
 
Unspecified(42)
 
 
Top Targets:
7tm 4(5)
 
 
 
Pyr redox dim(4)
 
 
 
PIKKc TOR(4)
 
 
SIS(3)
 
 
 
Hexokinase 2(3)
 
 
 
BioAssay Types:
Confirmatory(69)
 
 
 
 
Literature(54)
 
 
 
 
BioAssay Categories:
In vivo(5)
 
 
Biochemical(2)
 
 
Toxicity(21)
 
 
 
ADME(23)
 
 
 
Cell-based(4)
 
 
BioActivity Types:
Potency(68)
 
 
 
 
IC50(7)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 116    Data Row: 124   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103590232]
IC50 1.88Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay [AID562243, Type: Literature]
View
2
[SID103590232]
IC50 1.88Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry [AID562240, Type: Literature]
View
3
[SID103590232]
IC50 4.4Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay [AID562245, Type: Literature]
View
4
[SID103590232]
IC50 4.4Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry [AID562242, Type: Literature]
View
5
[SID103590232]
IC50 5.92Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry [AID562241, Type: Literature]
View
6
[SID103590232]
IC50 5.92Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay [AID562244, Type: Literature]
View
7
[SID90341625]
Potency 12.5893qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay [AID743207, Type: confirmatory]glucokinase isoform 1 [Homo sapiens] [gi:4503951]
View
8
[SID90341625]
Potency 12.5893qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay [AID743207, Type: confirmatory]glucokinase regulatory protein [Homo sapiens] [gi:221625433]
View
9
[SID90341625]
Potency 29.9349qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1) [AID488816, Type: confirmatory]flap endonuclease 1 [Homo sapiens] [gi:4758356]
View
10
[SID48415853]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
11
[SID49698631]
High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv [AID1332, Type: confirmatory]
View
12
[SID103590232]
Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] [AID1079941, Type: Literature]
View
13
[SID103590232]
Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] [AID1079939, Type: Literature]
View
14
[SID103590232]
Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] [AID1079942, Type: Literature]
View
15
[SID103590232]
Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] [AID1079943, Type: Literature]
View
16
[SID103590232]
Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] [AID1079935, Type: Literature]
View
17
[SID103590232]
Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source] [AID1079933, Type: Literature]
View
18
[SID103590232]
Animal toxicity known. [column 'TOXIC' in source] [AID1079945, Type: Literature]
View
19
[SID103590232]
Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] [AID1079931, Type: Literature]
View
20
[SID103590232]
Presence of at least one case with successful reintroduction. [column 'REINT' in source] [AID1079946, Type: Literature]
View